These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25477145)

  • 21. Sample sizes for batch acceptance from single- and multistage designs using two-sided normal tolerance intervals with specified content.
    Hauck WW; Shaikh R
    J Biopharm Stat; 2001 Nov; 11(4):335-46. PubMed ID: 12018783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sample size determination for testing equality in Poisson frequency data under an AB/BA crossover trial.
    Lui KJ
    Pharm Stat; 2013; 12(2):74-81. PubMed ID: 23364859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of Bayesian methods for multivariate bioequivalence measures.
    Molina de Souza R; Achcar JA; Martinez EZ
    J Biopharm Stat; 2009; 19(1):42-66. PubMed ID: 19127466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'.
    Montague TH; Potvin D; Diliberti CE; Hauck WW; Parr AF; Schuirmann DJ
    Pharm Stat; 2012; 11(1):8-13. PubMed ID: 21308974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence.
    Maurer W; Jones B; Chen Y
    Stat Med; 2018 May; 37(10):1587-1607. PubMed ID: 29462835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On sample size calculation in bioequivalence trials.
    Chow SC; Wang H
    J Pharmacokinet Pharmacodyn; 2001 Apr; 28(2):155-69. PubMed ID: 11381568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A simple numerical approach towards improving the two one-sided test for average bioequivalence.
    Cao L; Mathew T
    Biom J; 2008 Apr; 50(2):205-11. PubMed ID: 18383447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sample size determination for testing nonequality under a three-treatment two-period incomplete block crossover trial.
    Lui KJ; Chang KC
    Biom J; 2015 May; 57(3):410-21. PubMed ID: 25757940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-stage designs for cross-over bioequivalence trials.
    Kieser M; Rauch G
    Stat Med; 2015 Jul; 34(16):2403-16. PubMed ID: 25809815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blinded sample size re-estimation in crossover bioequivalence trials.
    Golkowski D; Friede T; Kieser M
    Pharm Stat; 2014; 13(3):157-62. PubMed ID: 24715672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exact sample-size determination in testing non-inferiority under a simple crossover trial.
    Lui KJ; Chang KC
    Pharm Stat; 2012; 11(2):129-34. PubMed ID: 22232060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S59-62. PubMed ID: 1601533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of the upper sample size limit in two-stage bioequivalence designs.
    Karalis V
    Int J Pharm; 2013 Nov; 456(1):87-94. PubMed ID: 23954235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Power Analysis and Sample Size Determination for Crossover Trials with Application to Bioequivalence Assessment of Topical Ophthalmic Drugs Using Serial Sampling Pharmacokinetic Data.
    Yu YP; Yan XY; Yao C; Xia JL
    Biomed Environ Sci; 2019 Aug; 32(8):614-623. PubMed ID: 31488237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
    Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
    Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1991 Jan; 29(1):1-8. PubMed ID: 2004861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On the use of the ratio or the odds ratio of cure rates in therapeutic equivalence clinical trials with binary endpoints.
    Tu D
    J Biopharm Stat; 1998 May; 8(2):263-82. PubMed ID: 9598422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sample size calculation for bioequivalence studies with high-order crossover designs.
    Qu RP; Zheng H
    Control Clin Trials; 2003 Aug; 24(4):436-9. PubMed ID: 12865037
    [No Abstract]   [Full Text] [Related]  

  • 40. Sequential design approaches for bioequivalence studies with crossover designs.
    Potvin D; DiLiberti CE; Hauck WW; Parr AF; Schuirmann DJ; Smith RA
    Pharm Stat; 2008; 7(4):245-62. PubMed ID: 17710740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.